# US 2024/0199662 A1 · Prodrugs of l-bhdu and methods of treating viral infections

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0199662 A1
- Document ID: US20240199662A1
- Status: Published application
- Kind: A1
- Application number: 18/435,109
- Filed: 2024-02-07
- Published: 2024-06-20
- Earliest claimed: 2021-10-29
- Assignees: University of Georgia Research Foundation, Inc.; Anterogen Co., Ltd.
- Applicants: University of Georgia Research Foundation, Inc.; Anterogen Co., Ltd.
- Inventors: Uma Sharan Singh; Chung Chu
- Web page: https://patentgrep.com/patent/US20240199662A1

## CPC

- C07F 9/65586: {at least one of the hetero rings does not contain nitrogen as ring hetero atom}
- A61K 31/675: having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 31/12: Antivirals
- A61P 31/22: for herpes viruses
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

In an embodiment, the invention is directed to prodrug compounds of L-BHDU according to the chemical structure I: Where R1 is a —(CH2)n—O—R1a group or a —(CH2)j—O—C(O)Ok—R2a group; R2 is H, a —(CH2)n—O—R1a group or a —(CH2)j—O—C(O)Ok— R2a group; R1a is independently a C6-C30alkyl group, often a C12-C22 alkyl group, often a C14-C20 alkyl group or a C16-C18 alkyl group, often a C16 or C18 alkyl group; R2a is independently a C1-C12 alkyl group, often a C2-C6 alkyl group, a C3-C4 alkyl group, an isopropyl, t-butyl or sec-butyl group, or an isopropyl or t-butyl group; Each j is independently 1-6, 1-3, often 1 or 2; Each k is 0 or 1; Each n is independently 1-6, 1-4, 2-4 or 2 or 3; or A pharmaceutically acceptable salt, solute or polymorph thereof. Additional embodiments are directed to pharmaceutical compositions based upon the disclosed chemical compounds and methods of treating or reducing the likelihood of VZV, HSV-1 or HSV-2 infections. Methods of synthesizing compounds according to the present invention represent further embodiments of the invention.

## Claims

### Claim 1

A prodrug compound of L-BHDU according to the chemical structure I:
Where R1 is a —(CH2)n—O—R1a group or a —(CH2)j—O—C(O)Ok—R2a group;
R2 is H, a —(CH2)n—O—R1a group or a —(CH2)j—O—C(O)Ok—R2 group;
R1a is independently a C6-C30 alkyl group, often a C12-C22 alkyl group, often a C14-C20 alkyl group or a C16-C18 alkyl group, often a C16 or C18 alkyl group;
R2a is independently a C1-C12 alkyl group, often a C2-C6 alkyl group, a C3-C4 alkyl group, an isopropyl, t-butyl or sec-butyl group, or an isopropyl or t-butyl group;
Each j is independently 1-6, 1-3, often 1 or 2;
Each k is 0 or 1;
Each n is independently 2-4; or
A pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

The compound according to claim 1 wherein R1 is a —(CH2)n—O—R1a group and n is 2 or 3.

### Claim 3 (depends on 1)

The compound according to claim 1 wherein R1a is a C16-C18 alkyl group and n is 2 or 3.

### Claim 4 (depends on 3)

The compound according to claim 3 wherein R1a is a C16 or C18 alkyl group and R2 is H.

### Claim 5 (depends on 4)

The compound according to claim 4 wherein R1a is C18 and n is 2.

### Claim 6 (depends on 4)

The compound according to claim 4 wherein R1a is C16 and n is 2.

### Claim 7 (depends on 3)

The compound according to claim 3, wherein R1 is a —(CH2)n—O—R1a group and R2 is H or —(CH2)n—O—R1a.

### Claim 8

(canceled)

### Claim 9 (depends on 1)

The compound according to claim 1 wherein R1 and R2 are each —(CH2)j—O—C(O)Ok—R2a groups and j is 1-4.

### Claim 10 (depends on 9)

The compound according to claim 9 wherein j is 1 and Ra is a C1-C12 alkyl group.

### Claim 11 (depends on 10)

The compound according to claim 10 wherein j is 1 and R2a is a C2-C6 alkyl group.

### Claim 12 (depends on 11)

The compound according to claim 11 wherein j is 1 and R2a is a C3 or C4 alkyl group.

### Claim 13

(canceled)

### Claim 14

(canceled)

### Claim 15 (depends on 9)

The compound according to claim 9 wherein j is 1 and R2a is a C4 alkyl group.

### Claim 16 (depends on 15)

The compound according to claim 15 wherein k is 0.

### Claim 17

(canceled)

### Claim 18

(canceled)

### Claim 19

A compound according to the chemical structure:
Where R1 is a —(CH2)n—O—R1a group, n is 2 or 3, R1a is a C16 or C18 alkyl group and R2 is H, or a pharmaceutically acceptable salt thereof.

### Claim 20 (depends on 19)

The compound according to claim 19 wherein n is 2 and R1a is a C18 alkyl group.

### Claim 21 (depends on 19)

The compound according to claim 19 wherein n is 2 or 3 and R1a is a C16 alkyl group.

### Claim 22

A compound according to the chemical structure:
Wherein R1 and R2 are each a —(CH2)j—O—C(O)Ok—R2a group;
R2a is independently an isopropyl or a t-butyl group;
Each j is 1;
Each k is 0 or 1; or
A pharmaceutically acceptable salt, solute or polymorph thereof.

### Claim 23 (depends on 22)

The compound according to claim 22 wherein R1 and R2 are identical, j is 1, k is 0 or 1 and R2a is an isopropyl group.

### Claim 24 (depends on 22)

The compound according to claim 22 wherein R1 and R2 are identical, j is 1, k is 0 and R2a is a tert-butyl group.

### Claim 25

A pharmaceutical composition comprising an effective amount of a compound according to the chemical structure:
or a
pharmaceutically acceptable salt thereof, in combination with a pharmaceutically acceptable carrier, additive or excipient.

### Claim 26 (depends on 25)

The composition according to claim 25 further including an additional bioactive agent.

### Claim 27 (depends on 26)

The composition according to claim 26 wherein said bioactive agent is acyclovir, brivudine, foscarnet, cidofovir (CDV), valacyclovir, famciclovir, zoster-immune globulin (ZIG), vidarabine or a mixture thereof.

### Claim 28 (depends on 26)

The composition according to claim 26 wherein said bioactive agent is 5-fluoro uracil.

### Claim 29 (depends on 27)

The composition according to claim 27 wherein said bioactive agent is foscarnet, cidovovir or a mixture thereof.

### Claim 30 (depends on 25)

A method of treating a viral infection in a patient in need comprising administering to said patient an effective amount of a composition according to claim 25, wherein the viral infection is a varicella zoster virus (VZV) infection, a herpes simplex virus I (HSV-1) infection or a herpes simplex virus II (HSV-2) infection.

### Claim 31 (depends on 30)

The method according to claim 30 wherein said virus infection is a VZV infection.

### Claim 32 (depends on 31)

The method according to claim 31 wherein said virus infection is caused by wild type VZV or mutant VZV (TK-, TS- or TK-TS-).

### Claim 33 (depends on 30)

The method according to claim 30 wherein said virus infection is a HSV-1 infection.

### Claim 34 (depends on 30)

The method according to claim 30 wherein said virus infection is a HSV-2 infection.

### Claim 35

A method of treating a viral infection in a patient in need comprising administering to said patient an effective amount of a compound according to the chemical structure:
or a
pharmaceutically acceptable salt thereof, wherein the viral infection is a varicella zoster virus (VZV) infection, a herpes simplex virus I (HSV-1) infection or a herpes simplex virus II (HSV-2) infection.

### Claim 36

(canceled)

### Claim 37 (depends on 25)

A method of reducing the likelihood of a viral infection in a patient in need comprising administering to said patient an effective amount of a composition according to claim 25, wherein the viral infection is a varicella zoster virus (VZV) infection, a herpes simplex virus I (HSV-1) infection or a herpes simplex virus II (HSV-2) infection.

### Claim 38 (depends on 37)

The method according to claim 37 wherein said virus infection is a VZV infection.

### Claim 39 (depends on 37)

The method according to claim 37 wherein said virus infection is a HSV-1 infection.

### Claim 40 (depends on 37)

The method according to claim 37 wherein said virus infection is a HSV-2 infection.

### Claim 41 (depends on 25)

A method of inhibiting or resolving complications of a VZV infection in a patient or subject in need, wherein said complications are postherpetic neuralgia, zoster multiplex, myelitis, herpes ophthalmicus, or zoster sine herpete, the method comprising administering a composition according to claim 25 to said patient or subject in need.

### Claim 42

(canceled)

### Claim at position 43

-48. (canceled)
